Head of Investor Relations Welcome to the Q3 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide number 3. Here we have the usual ...

Sanofi (EPA:SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected third-quarter results, ...

Treatment MarketThe global castration-resistant prostate cancer (CRPC) treatment market is poised for substantial growth, ...

The global vaccines market is poised for extraordinary growth, with projections indicating a Compound Annual Growth Rate (CAGR) of 6.6%. This anticipated expansion will elevate the market from its ...

On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...

Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped ...

Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full ...

Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat ...

Sanofi (SNY) has released an update. Sanofi reported a robust 15.7% growth in sales for Q3 2024, driven by strong performances in its vaccine ...

Sanofi is nearing a sale of a 50% stake in its consumer unit, valued at 16 billion euros in total, to boost clinical trials ...

ISLAMABAD: The Competition Commission of Pakistan (CCP) Friday approved the acquisition of trademarks for the pharmaceutical ...

Sanofi attributed its double-digit growth to growth in vaccines, particularly its latest flu jab. Another major revenue ...